Ruxolitinib cream has demonstrated efficacy and safety in adults with moderate atopic dermatitis. Dr Elaine Agius discusses a new TRuE AD4 analysis evaluating whether responses were consistent across different body sites, including sensitive areas such as the face and neck.

Research presented at the BAD 2026 Annual Meeting suggests that GLP-1 receptor agonists may improve inflammatory skin conditions, particularly psoriasis, through both weight-dependent and potentially direct anti-inflammatory effects. However, suspected adverse reactions, including alopecia, rash, pruritus and rare immune-mediated reactions, highlight the need for greater clinical awareness and further research.

New data from A-STAR offer real-world insights into systemic treatment use in atopic eczema, including drug survival and treatment patterns in older adults. Prof. Carsten Flohr also discusses how the register could evolve to support research, clinical decision-making, and greater patient involvement.

The FDA has cleared the first company-sponsored clinical study in peeling skin syndrome, allowing a phase 2 trial of QRX003 to begin later this year. The investigational topical therapy could represent an important step forward for a rare inherited skin disorder with no approved treatment.

To officially welcome Prof. Valenzuela to the Editorial Board and get to know him a little better, we invited him to reflect on what drew him to dermatology, the career experiences he has valued most, the advances that have transformed patient care and the innovations he hopes to see in the future. He also shares what he is most looking forward to in his new role with touchREVIEWS in Dermatology and the small things that brighten a busy working day.

The treatment landscape for vitiligo is evolving, with recent therapeutic advances, potential oral treatments, combination strategies and new consensus efforts helping to shape future care. In this expert interview, Prof. Viktoria Eleftheriadou discusses key takeaways from her BAD Annual Meeting session, including emerging systemic therapies, approaches to improving repigmentation outcomes and the importance of defining vitiligo severity beyond body surface area alone.

More than 35% of patients receiving zasocitinib achieved complete skin clearance, more than 2.5 times the response rate observed with deucravacitinib. [touchplayvideo video_id="mh592ao0iz"] In this video, we speak with Dr Linda Stein Gold (Henry Ford Health, Detroit, MI, ...

Targeting IL-36 signaling, imsidolimab significantly improved clear or almost clear skin responses at Week 4 compared with placebo in patients experiencing a generalized pustular psoriasis flare, with monthly maintenance treatment supporting sustained responses through 24 weeks.

From adjuvant immunotherapy in Merkel cell carcinoma to cellular therapy in advanced melanoma, late-breaking ASCO data offer new insights into evolving treatment strategies for difficult-to-treat skin cancers.